Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 63-67

  Iranzo, Vega ^a   Bremnes, Roy M ^b   Almendros, Piedad ^a   Gavilá, Joaquín ^a   Blasco, Ana ^a   Sirera, Rafael ^a   Camps, Carlos ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Chemoradiotherapy; Chemotherapy; Concurrent; Non small cell lung cancer; Radiotherapy; Sequential; Stage III

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; ESOPHAGITIS; ESOPHAGUS STENOSIS; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 57649109788     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.04.016     Document Type: Article

References (34)

1. Ettinger D.S. An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studies. Semin Oncol 32 (2005) S109-S110
2. Graham M.V., Pajak T.E., Herskovic A.M., Emami B., and Perez C.A. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results. Int J Radiat Oncol Biol Phys 31 (1995) 819-825
3. Le Chevalier T., Arriagada R., Quoix E., Ruffie P., Martin M., Tarayre M., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83 (1991) 417-423
4. Dillman R.O., Herndon J., Seagren S.L., Eaton Jr. W.L., and Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
5. Sause W., Kolesar P., Taylor IV S., Johnson D., Livingston R., Komaki R., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
6. Schaake-Koning C., van den B.W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
7. Pritchard R.S., and Anthony S.P. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125 (1996) 723-729
8. Pignon J.P., and Stewart L.A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. Cancer 77 (1996) 2413-2414
9. Mattson K., Holsti L.R., Holsti P., Jakobsson M., Kajanti M., Liippo K., et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24 (1988) 477-482
10. Morton R.F., Jett J.R., McGinnis W.L., Earle J.D., Therneau T.M., Krook J.E., et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 115 (1991) 681-686
11. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
12. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
13. Curran W.J., Scott C., Langer C., Komaki R., Lee J.S., Hauser S., et al. Phase III comparison of sequential vs concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19 (2000)
14. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23 (2005) 5883-5891
15. Auperin A., Le Pechoux C., Pignon J.P., Koning C., Jeremic B., Clamon G., et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 17 (2006) 473-483
16. Belderbos J., Uitterhoeve L., van Zandwijk N., Belderbos H., Rodrigus P., van d V., et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43 (2007) 114-121
17. Gandara D.R., Chansky K., Albain K.S., Leigh B.R., Gaspar L.E., Lara Jr. P.N., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21 (2003) 2004-2010
18. Vokes E.E., Herndon J.E., Crawford J., Leopold K.A., Perry M.C., Miller A.A., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20 (2002) 4191-4198
19. Stinchcombe T.E., Fried D., Morris D.E., and Socinski M.A. Combined modality therapy for stage III non-small cell lung cancer. Oncologist 11 (2006) 809-823
20. Glynne-Jones R., and Hoskin P. Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?. J Clin Oncol 25 (2007) 5281-5286
21. Huber R.M., Flentje M., Schmidt M., Pollinger B., Gosse H., Willner J., et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 24 (2006) 4397-4404
22. Socinski M.A., and Bogart J.A. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol 25 (2007) 4137-4145
23. Rigas J.R., and Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2 Suppl. 2 (2007) S77-S85
24. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
25. Rowell N.P., and O'Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev (2004) CD002140
26. Fournel P., Robinet G., Thomas P., Souquet P.J., Lena H., Vergnenegre A., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 (2005) 5910-5917
27. Saunders M.I., Dische S., Barrett A., Parmar M.K., Harvey A., and Gibson D. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. Br J Cancer 73 (1996) 1455-1462
28. Socinski M.A., Morris D.E., Halle J.S., Moore D.T., Hensing T.A., Limentani S.A., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 22 (2004) 4341-4350
29. Saunders M.I., Dische S., Grosch E.J., Fermont D.C., Ashford R.F., Maher E.J., et al. Experience with CHART. Int J Radiat Oncol Biol Phys 21 (1991) 871-878
30. Cox J.D., Azarnia N., Byhardt R.W., Shin K.H., Emami B., and Pajak T.F. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8 (1990) 1543-1555
31. Belani C.P., Wang W., Johnson D.H., Wagner H., Schiller J., Veeder M., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23 (2005) 3760-3767
32. Lau D., Leigh B., Gandara D., Edelman M., Morgan R., Israel V., et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 19 (2001) 442-447
33. Kaplan B., Altynbas M., Eroglu C., Karahacioglu E., Er O., Ozkan M., et al. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC). Am J Clin Oncol 27 (2004) 603-610
34. Senan S. Staging nodal disease in non-small cell lung cancer: implications for radiation therapy. J Thorac Oncol 2 (2007) 585-587